The natural history of breast carcinoma in patients with ≥ 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: A multiinstitutional retrospective study

Cancer

Volumn 104, Issue 2, 2005, Pages 229-235

  Montero, Alberto J ^a   Rouzier, Roman ^b   Lluch, Ana ^c   Theriault, Richard L ^a   Buzdar, Aman U ^a   Delaloge, Suzette ^b   Bermejo, Begoñia ^c   Le, Monique ^b   Kau, Shu Wan ^a   Dunant, Ariane ^b   Arrìagada, Rodrìgo ^b   Spielmann, Marc ^b   García Conde, Javier ^c   Sahin, Aysegul A ^a   Singletary, Sonja E ^a   Hortobagyi, Gabriel N ^a   Valero, Vicente ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

> 10 axillary lymph nodes; Adjuvant therapy; Anthracyclines; Breast carcinoma

Indexed keywords

ANTHRACYCLINE; ESTROGEN RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAMOXIFEN;

EID: 22244446421     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21182     Document Type: Article

References (19)

1. Recht A, Houlihan MJ. Axillary lymph nodes and breast cancer: a review. Cancer. 1995;76:1491-1512.
2. Fisher B, Bauer M, Wickerham DL, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer. 1983;52: 1551-1557.
3. Buzdar AU, Kau SW, Hortobagyi GN, et al. Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy. Cancer. 1992;69:448-452.
4. Fisher ER, Costantino J, Fisher B, Redmond C. Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol 4). Discriminants for 15-year survival. National Surgical Adjuvant Breast and Bowel Project Investigators. Cancer. 1993;71:2141-2150.
5. Carlson RW, Wheatley K. High-dose chemotherapy and stem cell transplantation does not improve relapse-free or overall survival in women with high-risk breast cancer. Cancer Treat Rev. 2004;30:131-137.
6. Zander AR, Kroger N, Schmoor C, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol. 2004;22:2273-2283.
7. Walker MJ, Osborne MD, Young DC, et al. The natural history of breast cancer with more than 10 positive nodes. Am J Surg. 1995;169:575-579.
8. Tsuchiya A, Kanno M, Abe R. The impact of lymph node metastases on the survival of breast cancer patients with ten or more positive lymph nodes. Surg Today. 1997;27:902-906.
9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc J. 1958;53:457-481.
10. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187-202.
11. Jones SE, Moon TE, Bonadonna G, et al. Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history database. Am J Clin Oncol. 1987;10:387-395.
12. Wilson RE, Donegan WL, Mettlin C, et al. The 1982 national survey of carcinoma of the breast in the United States by the American College of Surgeons. Surg Gynecol Obstet. 1984; 159:309-318.
13. Diab SG, Hilsenbeck SG, de Moor C, et al. Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. J Clin Oncol. 1998;16:1655-1660.
14. Martin M, Pienkowski T, Mackey J, et al. TAC improves disease-free survival and overall survival over FAC in node-positive early breast cancer patients, BCIRG 001: 55 months follow-up. 26th Annual San Antonio Breast Cancer Symposium [abstract]. Breast Ca Res Treat. 2003;81:43.
15. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as post-operative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21: 1431-1439.
16. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081-1092.
17. Goss PE, Ingle JN, Martine S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793-1802.
18. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol. 2000;18:3758-3767.
19. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (arimidex, tamoxifen alone or in combination) trial 4fficacy and safety update analyses. Cancer. 2003;9B:1802-1810.